Form 4: ADMA Biologics COO Tax Withholding on RSU Vesting

ADMA Biologics' COO and SVP of Compliance, Kaitlin M. Kestenberg-Messina, reported the withholding of 8,161 shares for tax obligations related to RSU vesting.

Summary

• Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, reported a transaction on February 19, 2026.
• The transaction involved the disposition of 8,161 shares of common stock at a price of $16.32 per share.
• This disposition was not an open market sale but represented shares withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs).
• Following this transaction, Kestenberg-Messina beneficially owns 572,160 shares, which includes a mix of directly owned common stock and various tranches of unvested RSUs.
• The unvested RSUs include grants from February 2026 (91,631 units), February 2025 (58,338 units), April 2024 (144,240 units), July 2023 (15,000 units), March 2023 (47,500 units), and March 2022 (10,000 units), all vesting quarterly over four years.
• Directly owned common stock totals 205,451 shares, reflecting prior option exercises and net RSU settlements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine transaction indicating RSU vesting, which is a positive for executive retention and alignment, with no negative implications for the company's operations or outlook.

Positives

• The transaction is a routine tax withholding event, indicating the vesting of previously granted restricted stock units (RSUs) for a key executive.
• The executive continues to hold a significant beneficial ownership of 572,160 shares, demonstrating continued alignment with shareholder interests.
• The vesting of RSUs suggests the executive has met service conditions, indicating stability in key management roles.

Negatives

• A disposition of shares, even for tax purposes, reduces the executive's direct share count, albeit temporarily.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, as it is a report of a past transaction related to executive compensation.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as tax withholdings upon RSU vesting, are common across all industries, particularly in established biotechnology or pharmaceutical companies like ADMA Biologics. These events typically reflect the normal course of executive compensation and do not usually signal a change in company fundamentals or strategic direction. Competitors often see similar filings from their executives as part of their compensation structures.

Comparison to Industry Standards

• This transaction is a standard practice for executive compensation in publicly traded companies, particularly those utilizing Restricted Stock Units (RSUs) as part of their long-term incentive plans.
• Companies across various sectors, including biotech firms like Regeneron Pharmaceuticals (REGN) or Amgen (AMGN), frequently report similar Form 4 filings where executives have shares withheld for tax purposes upon RSU vesting.
• The volume of shares withheld (8,161) relative to the executive's total beneficial ownership (572,160) is typical for such a transaction, representing a small fraction of their overall stake and reflecting the tax liability on vested equity.

Stakeholder Impact

• Shareholders: The transaction is a routine administrative event and is unlikely to have a direct material impact on existing shareholders. It confirms the ongoing compensation structure for a key executive.
• Employees: The vesting of RSUs for a senior executive may reinforce the company's compensation philosophy and long-term incentive programs for other employees.

Key Dates

Recommendation

This Form 4 filing reports a routine tax-related disposition of shares by a key executive upon RSU vesting. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. The executive's continued significant beneficial ownership, including substantial unvested RSUs, suggests ongoing alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

ADMA Biologics, ADMA, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Kaitlin M. Kestenberg-Messina, Beneficial Ownership